Artikel ; Online: High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma.
2024 Band 49, Heft 7, Seite(n) 610–620
Abstract: Patients and methods: The primary endpoints were objective response rate (ORR) and disease control rate (DCR). Secondary endpoints were duration of response, blood pressure control, safety, overall and progression-free survival rates, MIBG uptake, and ... ...
Abstract | Patients and methods: The primary endpoints were objective response rate (ORR) and disease control rate (DCR). Secondary endpoints were duration of response, blood pressure control, safety, overall and progression-free survival rates, MIBG uptake, and correlations with genetic background. Results: The study included 25 patients. Twenty-four patients had distant metastases, 17 (68%) had hormonally active tumors, and 13 (52%) had previously received antineoplastic treatment. In 24 evaluable patients, the ORR was 38%, including 2 patients with complete response, and the DCR was 83%; median time to response was 12.5 months (95% confidence interval, 4.6-25.1). Twelve patients had sporadic disease, among whom the ORR was 25% and DCR was 83%. Twelve patients had hereditary disease ( SDHB , VHL , RET ); among these, the ORR was 50%, and DCR was 83%. Plasma metanephrines normalized in 30% of patients and improved by greater than 50% in 46%. Sixteen patients had hormonally active tumors and hypertension; in 9 (56%) of these, blood pressure normalized, leading to discontinuation of antihypertensive therapy.The most common adverse events were grades 1-2 nausea/vomiting and transient bone marrow suppression. One patient developed premature ovarian failure. Reversible grades 3-4 myelosuppression were seen in 7 patients (28%). One patient had fatal pneumonitis. Conclusions: HSA- 131 I-MIBG is associated with a high DCR in patients with MPPGL, regardless of underlying genetic mutation. |
---|---|
Mesh-Begriff(e) | Humans ; Pheochromocytoma/diagnostic imaging ; Pheochromocytoma/radiotherapy ; Pheochromocytoma/drug therapy ; Female ; Male ; Paraganglioma/radiotherapy ; Paraganglioma/diagnostic imaging ; Paraganglioma/drug therapy ; Adult ; Middle Aged ; Adrenal Gland Neoplasms/diagnostic imaging ; Adrenal Gland Neoplasms/radiotherapy ; 3-Iodobenzylguanidine ; Aged ; Young Adult ; Treatment Outcome ; Adolescent ; Iodine Radioisotopes |
Chemische Substanzen | 3-Iodobenzylguanidine (35MRW7B4AD) ; Iodine-131 ; Iodine Radioisotopes |
Sprache | Englisch |
Erscheinungsdatum | 2024-04-17 |
Erscheinungsland | United States |
Dokumenttyp | Journal Article |
ZDB-ID | 197628-x |
ISSN | 1536-0229 ; 0363-9762 |
ISSN (online) | 1536-0229 |
ISSN | 0363-9762 |
DOI | 10.1097/RLU.0000000000005184 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 1276: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.